EUCTR2022-000461-41-BG招募中1 期
A Randomized, Double-blind, Multicenter, Parallel-Group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. - VENTURA-2
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 538
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •- Male or female, aged 18 to 74 years of age, inclusive.
- •- Be medically stable on the basis of physical examination, medical history, vital signs, and 12-lead ECG performed at screening and baseline
- •- Be medically stable on the basis of clinical laboratory tests performed at screening
- •- Meet DSM-5 diagnostic criteria for recurrent or single episode MDD, without psychotic features. Participants 65 years of age or older must have had the first onset of depression prior to 55 years of age.
- •- Have had an inadequate response to at least 1 oral antidepressant treatment administered at an adequate dose (at or above the minimum therapeutic dose per MGH ATRQ) and duration (at least 6 weeks) in the current episode of depression.
- •- Is currently receiving and tolerating well a SSRI/SNRI for depressive symptoms at screening, at a stable dose (at or above the minimum therapeutic dose per MGH ATRQ) for at least 6 weeks.
- •- Have a HDRS-17 total score of 20 or higher at the first and second screening interviews and must not demonstrate a clinically significant improvement between the first and the second independent HDRS-17 assessments
- •For a full list of inclusion criteria, please refer to the study protocol
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 430
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 108
排除标准
- •- Have had in the current depressive episode, no response (treatment failure) to 5 or more antidepressant treatments including the current SSRI/SNRI (ie, the one presumed to be continued in the treatment phase) assessed using the MGH ATRQ.
- •- Has one or more of the following diagnoses:
- •*A DSM-5 diagnosis (which has been the primary focus of psychiatric treatment within the past 2 years)of any of the following: panic disorder, generalized anxiety disorder, social anxiety disorder, specific phobia.
- •* current (in the past year) DSM-5 diagnosis of: obsessive-compulsive disorder, post-traumatic stress disorder, anorexia nervosa, bulimia nervosa
- •* A current or prior (lifetime) DSM-5 diagnosis of: a psychotic disorder or MDD with psychotic features, bipolar or related disorders, intellectual disability, autism spectrum disorder, borderline personality disorder, antisocial personality disorder, histrionic personality disorder, narcissistic personality disorders, somatoform disorders.
- •- Has a history or evidence of clinically meaningful noncompliance with current antidepressant therapy.
- •- Has a history of moderate-to-severe substance use disorder including alcohol use disorder according to DSM-5 criteria within 6 months before screening
- •- Has had in the current episode an inadequate response to adequate course of intravenous or intranasal ketamine or esketamine, electroconvulsive therapy (i.e, at least 7 treatments), vagal nerve stimulation, or deep brain stimulation device
- •- Has a current homicidal ideation/intent, per the investigator’s clinical judgment, or has suicidal ideation with some intent to act within 3 months prior to the start of the screening phase
- •For a full list of exclusion criteria, please refer to the study protocol
研究者
相似试验
招募中
1 期
A study to evaluate the effectiveness of aticaprant as an add on treatment in patients with depression who have not responded sufficiently to their current antidepressant.Major Depressive Disorder (MDD)MedDRA version: 21.1Level: LLTClassification code 10025453Term: Major depressive disorder NOSSystem Organ Class: 100000004873EUCTR2022-000439-22-SEJanssen-Cilag International NV538
进行中（未招募）
1 期
Clinical trial to compare the efficacy, distribution within the body, safety and immune response between Bmab 1000 and Prolia in Postmenopausal Women with OsteoporosisPostmenopausal women diagnosed with osteoporosisMedDRA version: 20.0Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2021-006545-36-PLBiocon Biologics UK Limited480
招募中
1 期
A study to evaluate the effectiveness of aticaprant as an add on treatment in patients with depression who have not responded sufficiently to their current antidepressant.Major Depressive Disorder (MDD)MedDRA version: 21.1Level: LLTClassification code 10025453Term: Major depressive disorder NOSSystem Organ Class: 100000004873EUCTR2022-000439-22-BGJanssen-Cilag International NV538
进行中（未招募）
1 期
A study to evaluate the effectiveness of aticaprant as an add on treatment in patients with depression who have not responded sufficiently to their current antidepressant.Major Depressive Disorder (MDD)MedDRA version: 21.1Level: LLTClassification code 10025453Term: Major depressive disorder NOSSystem Organ Class: 100000004873EUCTR2022-000439-22-CZJanssen-Cilag International NV538
招募中
1 期
A study to evaluate the effectiveness of aticaprant as an add on treatment in patients with depression who have not responded sufficiently to their current antidepressant.Major Depressive Disorder (MDD)MedDRA version: 21.1Level: LLTClassification code 10025453Term: Major depressive disorder NOSSystem Organ Class: 100000004873EUCTR2022-000439-22-PLJanssen-Cilag International NV538